Virtual Reality-Based Cognitive-Motor Rehabilitation in Traumatic Brain Injury

November 10, 2026 updated by: Dr. Gabriel Zeilig

Novel Virtual Reality-Based Cognitive-Motor Rehabilitation for Individuals With Traumatic Brain Injury

This study aims to evaluate the feasibility, safety, and efficacy of a novel virtual reality (VR)-based cognitive-motor rehabilitation program for individuals with traumatic brain injury (TBI). The intervention uses the Virtual Reality Color Trails Test (VR-CTT), which combines cognitive tasks with upper-limb movements in an immersive virtual environment.

The study consists of two stages. The first stage is a feasibility pilot involving 15 participants who will complete three VR training sessions over one week. The second stage is a randomized controlled trial involving 80 participants allocated to either VR-CTT training combined with standard rehabilitation or a control group receiving standard rehabilitation with additional therapy time. The intervention will consist of nine sessions over three weeks.

The study will assess feasibility, safety, executive functions, upper-limb motor performance, balance, and functional outcomes.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Traumatic brain injury (TBI) frequently results in cognitive and motor impairments that affect everyday functioning. Conventional rehabilitation often addresses these domains separately, although many daily activities require their simultaneous integration. This study evaluates a rehabilitation approach based on the Virtual Reality Color Trails Test (VR-CTT), an immersive system developed at Sheba Medical Center that combines cognitive challenges with coordinated head and upper-limb movements.

The study consists of two sequential stages.

**Stage 1: Feasibility Pilot**

Fifteen participants with TBI will receive three VR-CTT training sessions over one week in addition to standard rehabilitation. Training will progress from seated tasks to more challenging standing activities according to individual abilities. This stage will assess feasibility, safety, usability, and participant satisfaction to inform implementation of the subsequent trial.

**Stage 2: Randomized Controlled Trial**

Eighty participants with TBI will be randomly assigned in a 1:1 ratio to two parallel groups. The intervention group will receive standard rehabilitation supplemented by nine VR-CTT training sessions over three weeks. Training difficulty will increase progressively through changes in cognitive demands, the number of targets, body position, and unilateral or bilateral hand use.

The control group will receive standard rehabilitation supplemented by additional cognitive or motor therapy to match the total treatment time of the intervention group.

Outcome assessments will be conducted before and after the intervention period and will include measures of executive functioning, upper-limb motor performance, balance, everyday functioning, and cognitive-motor interaction. Outcome assessors will remain blinded to group allocation during the randomized stage.

The study aims to determine whether integrated VR-based cognitive-motor training is feasible and safe and whether it improves cognitive and motor outcomes compared with conventional rehabilitation.

Study Type

Interventional

Enrollment (Estimated)

95

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Ramat Gan, Israel
        • Sheba Medical Center
        • Contact:
        • Sub-Investigator:
          • Meir Plotnik, Prof.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 50 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

**Inclusion Criteria:**

  1. Men and women aged 18-50 years.
  2. Admitted for inpatient rehabilitation following traumatic brain injury (TBI).
  3. Glasgow Coma Scale (GCS) score of 9-15 at admission.
  4. Brain CT positive for acute intracranial trauma (including complicated mild or moderate TBI).
  5. Presence of cognitive and motor symptoms as determined by clinical evaluation.
  6. Sufficient decision-making capacity to provide informed consent.

**Exclusion Criteria:**

  1. Inability to meaningfully comprehend the study procedures (e.g., severe aphasia or cognitive impairment), as determined through a structured capacity assessment.
  2. Severe physical limitations that prevent the use of VR equipment (e.g., severe upper-limb fractures preventing controller use).
  3. History of epilepsy or seizures triggered by flashing lights.
  4. Severe visual or vestibular impairments that would make VR exposure unsafe (e.g., severe vertigo).
  5. Active psychiatric conditions (e.g., acute psychosis) likely to interfere with adherence to study procedures.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Stage 1: VR-CTT Feasibility Pilot

Fifteen participants with traumatic brain injury will receive standard rehabilitation supplemented by three VR-CTT training sessions over one week. Sessions will last approximately 45 minutes and progress from seated activities to standing activities according to participants' abilities. This stage will evaluate feasibility, safety, and usability.

An immersive virtual reality-based cognitive-motor rehabilitation program using the HTC VIVE system and custom-developed VR-CTT software. Participants perform cognitive tasks involving visual search, attention, and cognitive flexibility while reaching toward virtual targets using coordinated upper-limb and head movements. Training difficulty is progressively adjusted by modifying the number of targets, cognitive demands, posture, and hand use. The intervention consists of three sessions over one week in Stage 1 and nine sessions over three weeks in Stage 2.

Experimental: Stage 2: VR-CTT Training

Forty participants will receive standard inpatient rehabilitation supplemented by nine VR-CTT training sessions over three weeks (three sessions per week, approximately 45 minutes each). Training will progressively increase cognitive and motor demands through changes in target number, task complexity, posture, and hand use.

An immersive virtual reality-based cognitive-motor rehabilitation program using the HTC VIVE system and custom-developed VR-CTT software. Participants perform cognitive tasks involving visual search, attention, and cognitive flexibility while reaching toward virtual targets using coordinated upper-limb and head movements. Training difficulty is progressively adjusted by modifying the number of targets, cognitive demands, posture, and hand use. The intervention consists of three sessions over one week in Stage 1 and nine sessions over three weeks in Stage 2.

Active Comparator: Stage 2: Active Control

Forty participants will receive standard inpatient rehabilitation supplemented by approximately three hours per week of additional cognitive or motor therapy with a therapist or volunteer, without VR-CTT training. The additional therapy is intended to match the total treatment time of the intervention group.

Additional cognitive or motor rehabilitation exercises administered by a therapist or volunteer, supplementing standard inpatient rehabilitation. Participants receive approximately three hours of additional therapy per week over three weeks to match the total treatment time provided to the VR-CTT intervention group.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Executive Function Composite Score
Time Frame: Baseline (Week 0) and post-intervention (Week 4).

Change in executive functioning assessed using a composite score derived from the Stroop Test, Rule Shift Cards Test (BADS), and Montreal Cognitive Assessment (MoCA). Standardized scores will be used to evaluate changes in executive control, including inhibition, cognitive shifting, and mental flexibility.

Baseline (Week 0) and post-intervention (Week 4).
Change in Upper Limb Motor Function (ARAT)
Time Frame: Baseline (Week 0) and post-intervention (Week 4).

Change in upper limb motor function assessed using the Action Research Arm Test (ARAT), which evaluates upper extremity motor performance and coordination. Higher scores indicate better motor function.

Baseline (Week 0) and post-intervention (Week 4).

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Functional Status (FSE)
Time Frame: Baseline (Week 0) and post-intervention (Week 4).

Change in everyday functional outcomes assessed using the Functional Status Examination (FSE), which evaluates functional limitations following traumatic brain injury.

Baseline (Week 0) and post-intervention (Week 4).
Change in Balance (Berg Balance Scale)
Time Frame: Baseline (Week 0) and post-intervention (Week 4).

Change in static and dynamic balance assessed using the Berg Balance Scale (BBS). Higher scores indicate better balance performance.

Baseline (Week 0) and post-intervention (Week 4).
Change in Cognitive-Motor Performance (VR Supermarket Task)
Time Frame: Baseline (Week 0) and post-intervention (Week 4).

Change in performance on a virtual reality-based supermarket task assessing cognitive-motor integration, including divided attention and sustained attention during simulated everyday activities.

Baseline (Week 0) and post-intervention (Week 4).
Change in Dual-Task Performance (Box and Block Test)
Time Frame: Baseline (Week 0) and post-intervention (Week 4).

Change in dual-task performance assessed using the Dual-Task Box and Block Test (BBT-DT), in which participants transfer blocks while simultaneously performing mental arithmetic.

Baseline (Week 0) and post-intervention (Week 4).
Feasibility of VR-CTT Training
Time Frame: During the one-week pilot intervention (Stage 1).

Feasibility assessed by adherence to the planned VR-CTT training protocol, including the proportion of scheduled training sessions completed by participants.

During the one-week pilot intervention (Stage 1).
Simulator Sickness Symptoms
Time Frame: After each VR training session during the one-week pilot (Stage 1).

Simulator sickness symptoms, including nausea, dizziness, headache, and eyestrain, assessed after VR training sessions using the Simulator Sickness Questionnaire (SSQ).

After each VR training session during the one-week pilot (Stage 1).
VR-CTT Usability and Participant Satisfaction
Time Frame: At completion of the one-week pilot intervention (Stage 1).

Usability and participant satisfaction with the VR-CTT system assessed using post-training feedback questionnaires addressing comfort, ease of use, and overall experience.

At completion of the one-week pilot intervention (Stage 1).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2026

Primary Completion (Estimated)

December 1, 2029

Study Completion (Estimated)

December 1, 2029

Study Registration Dates

First Submitted

November 10, 2026

First Submitted That Met QC Criteria

November 10, 2026

First Posted (Actual)

November 17, 2026

Study Record Updates

Last Update Posted (Actual)

November 17, 2026

Last Update Submitted That Met QC Criteria

November 10, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • SHEBA-26-3045-GZ-CTIL

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.